Radiation Therapy News and Research RSS Feed - Radiation Therapy News and Research

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.
Childhood cancer survivors have high risk of suffering stroke at young age

Childhood cancer survivors have high risk of suffering stroke at young age

Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood cancer have a high risk of suffering a stroke at a surprisingly young age. [More]
Researchers find that 26% of senior oncology patients use complementary or alternative medicines

Researchers find that 26% of senior oncology patients use complementary or alternative medicines

Alternative medicines are widely thought to be at least harmless and very often helpful for a wide range of discomforts and illnesses. However, although they're marketed as "natural," they often contain active ingredients that can react chemically and biologically with other therapies. [More]
ASTRO awards $675,000 to seven physician-researchers to advance radiation oncology research

ASTRO awards $675,000 to seven physician-researchers to advance radiation oncology research

The American Society for Radiation Oncology has selected seven leading physician-researchers to receive a total of $675,000 in awards and grants to advance radiation oncology research. Together, the seven funding grants, including ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Award and the ASTRO/Radiation Oncology Institute Comparative Effectiveness Research Award, will support studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology. [More]
Irreversible electroporation may prolong survival rates of patients with locally advanced pancreatic cancer

Irreversible electroporation may prolong survival rates of patients with locally advanced pancreatic cancer

Use of irreversible electroporation (IRE) doubles the survival time for patients with locally advanced pancreatic cancer say researchers at the University of Louisville in a paper in the September edition of the Annals of Surgery. [More]
Study sheds light on fertility concerns of young breast cancer patients

Study sheds light on fertility concerns of young breast cancer patients

Concerns about fertility kept a third of young women with breast cancer from taking tamoxifen, despite its known benefit in reducing the risk of breast cancer coming back. [More]
UT System Board of Regents approves new UT Southwestern Monty and Tex Moncrief Medical Center

UT System Board of Regents approves new UT Southwestern Monty and Tex Moncrief Medical Center

The University of Texas System Board of Regents has approved establishment of the UT Southwestern Monty and Tex Moncrief Medical Center at Fort Worth, made possible by an extraordinary $25 million commitment from W.A. "Tex" Moncrief Jr. The Center is UT Southwestern's first named campus outside of Dallas. [More]
New partnering scholarship launched to inspire and develop potential oncology nurses

New partnering scholarship launched to inspire and develop potential oncology nurses

As experienced oncology nurses know, a cancer diagnosis is only the first step on a long and challenging road ahead—for patients and providers alike. For both, a wide range of procedures becomes part and parcel of every day. [More]
Johns Hopkins experts say hospital consolidation may reduce patient choice, increase medical expenses

Johns Hopkins experts say hospital consolidation may reduce patient choice, increase medical expenses

In a commentary published in the Aug. 13 issue of JAMA, Johns Hopkins experts say consolidation of hospitals into massive chains threatens healthy competition, reduces patient choice and could drive up medical expenses. [More]
First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma. [More]
MGH study reveals effects of combined radiation and chemotherapy on the brain tissue of glioblastoma patients

MGH study reveals effects of combined radiation and chemotherapy on the brain tissue of glioblastoma patients

A study from Massachusetts General Hospital Cancer Center researchers - the first to examine the effects of combined radiation and chemotherapy on the healthy brain tissue of glioblastoma patients - reveals not only specific structural changes within patients' brains but also that the effect of cancer therapy on the normal brain appears to be progressive and continues even after radiation therapy has ceased. [More]
FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly. [More]
New system accurately and reliably captures patient experience with cancer drug side effects

New system accurately and reliably captures patient experience with cancer drug side effects

In cancer clinical trials, symptom side effects patients experience, like nausea, are typically reported by doctors, and not directly by patients. Previous research has shown that doctors under-report these symptoms. [More]
Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Merck and The University of Texas MD Anderson Cancer Center announced a strategic clinical research collaboration to evaluate Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with other treatments, such as chemotherapy, radiation therapy and/or novel anti-tumor medicines. [More]
Cost of radiation therapy varies widely among Medicare patients with cancer

Cost of radiation therapy varies widely among Medicare patients with cancer

Cost of radiation therapy among Medicare patients varied most widely because of factors unrelated to a patient or that person's cancer, report University of California, San Diego School of Medicine researchers in the Journal of Oncology Practice. [More]
Novel combination therapy effective at treating patients with skin metastases

Novel combination therapy effective at treating patients with skin metastases

In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown. [More]
Seventeen distinguished members of ASTRO selected to receive Fellows designation

Seventeen distinguished members of ASTRO selected to receive Fellows designation

The American Society for Radiation Oncology has selected 17 distinguished members to receive the ASTRO Fellows designation. The 2015 class of Fellows will receive the recognition at the Awards Ceremony at ASTRO's 57th Annual Meeting on Tuesday, October 20 at the Henry B. Gonzalez Convention Center in San Antonio. [More]
SCCA Proton Therapy Center makes advanced radiation therapy accessible to patients with ocular melanoma

SCCA Proton Therapy Center makes advanced radiation therapy accessible to patients with ocular melanoma

For most the ability to see is often taken for granted. But for the thousands diagnosed with ocular melanoma, the fear of losing their eyesight or even worse, their lives, is an all too real possibility. Ocular melanoma is seen as a rare form of cancer, with approximately two thousand new diagnoses per year. [More]
Shorter course of whole breast radiation therapy better for women with early stage breast cancer

Shorter course of whole breast radiation therapy better for women with early stage breast cancer

Women who receive a shorter course of whole breast radiation therapy for early stage disease experience less toxicity and improved quality of life compared to those who undergo a longer course of treatment, researchers report from The University of Texas MD Anderson Cancer Center. [More]
Allergan receives FDA approval to market 28 additional styles of Natrelle 410 silicone-filled breast implants

Allergan receives FDA approval to market 28 additional styles of Natrelle 410 silicone-filled breast implants

Allergan, plc. today announced that the company has received approval from the U.S. Food and Drug Administration to market 28 additional styles of Natrelle 410 silicone-filled breast implants, giving surgeons and patients more options to achieve desired outcomes. [More]
EORTC study: Irradiation of regional nodes in breast cancer patients has marginal effect on overall survival

EORTC study: Irradiation of regional nodes in breast cancer patients has marginal effect on overall survival

At a median follow-up of 10.9 years, an EORTC study has shown that irradiation of regional nodes in patients with stage I, II, or III breast cancer has a marginal effect on overall survival, the primary endpoint (at 10 years, overall survival was 82.3 % for regional irradiation versus 80.7% for no regional irradiation, (HR=0.87 (95%CI: 0.76, 1.00), p=0.06). [More]
Advertisement
Advertisement